Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

. 2003 Oct;2(5):1003–1008. doi: 10.1128/EC.2.5.1003-1008.2003

TABLE 1.

Drug resistance phenotype of the tbat1-null mutant compared to the parental wild-type strain

Drug IC50a (ng/ml)
Resistance factor
Wild type TbAT1−/− mutant
Melarsoprol 21 ± 3 49 ± 9 2.3
Melarsen oxide 3.7 ± 0.1 11 ± 0.1 3.0
Cymelarsan 6.1 ± 1 12 ± 3 2.0
Pentamidine 5.1 ± 2 12 ± 3 2.4
Diminazene 120 ± 30 2,300 ± 500 19
Propamidine 67 ± 7 750 ± 20 11
Stilbamidine 680 ± 70 5,000 ± 1,300 7.4
a

IC50 were determined in vitro by using the Alamar Blue assay. Values are means from at least three independent experiments ± standard errors.

HHS Vulnerability Disclosure